A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Induction of Levodopa-Induced Dyskinesias in a Rat Model of Parkinson's Disease

1.2K views

July 8th, 2025

In This Article

Abstract

Source: Caulfield, M. E., et al. Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease. J. Vis. Exp. (2021).

This video demonstrates the process of inducing levodopa-induced dyskinesias in a Parkinson's rat model by administering levodopa alongside a dopamine conversion inhibitor. Repeated injections overstimulate the brain neurons, resulting in motor dysfunction.

Protocol

All procedures involving animal models have been reviewed by the local institutional animal care committee and the JoVE veterinary review board.

1. Preparation of reagents and supplies

  1. Determine L-3,4-dihydroxyphenylalanine methyl ester hydrochloride (levodopa or L-DOPA) and benserazide hydrochloride, a peripheral decarboxylase inhibitor (see Table of Materials) dose, rating frequency, and experimental timeline that is appropriate for the investigational question (Figure 1).
    NOTE: Investigational questions can be posed to seek any number of answers, rang....

Access restricted. Please log in or start a trial to view this content.

Results

LID prevention timeline diagram, showing experimental treatment duration and LID rating intervals.
Figure 1: Example of treatment timeline. Example L-DOPA dose-escalation timeline of 12 weeks in total length, with 8 weeks of L-DOPA injections beginning 3 weeks after 6-OHDA lesioning and 4 weeks following experimental treatment. In this example, L-DOPA .......

Access restricted. Please log in or start a trial to view this content.

Disclosures

No conflicts of interest declared.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
100 Minutes Digital TimerStaples1111764
Compass CX Compact ScaleOhaus30428202
5-(2-aminoethyl)-1,2,4-benzenetriol, monohydrobromideCayman Chemicals253306-OHDA is a catecholaminergic neurotoxin that is used to induce dopaminergic lesions and parkinsonian symptoms in rodents.
Allentown cagesAllentown, LLCRat900Allentown cages provide the ability to view the rats from all sides.
BD Allergist Trays with Permanently Attached NeedleBDBD 305540For subcutaneous L-DOPA injections
Benserazide hydrochlorideSigma-AldrichB7283Benserazide is a peripheral decarboxylase inhibitor used with L-DOPA to to induce dyskinesia in rodent models of PD.
Glass amber scintillation vialsThermo ScientificB7921Used for storage of L-DOPA/benserazide at -20 °C until mixed with sterile saline.
L-3,4-Dihydroxyphenylalanine methyl ester hydrochlorideSigma-AldrichD1507L-3,4-Dihydroxyphenylalanine methyl ester is a precursor to L-DOPA that crosses the blood-brain barrierand use to treat parkinsonian symptoms in rodents.
Paper Mate Sharpwriter Mechanical PencilsStaples107250
Rodent nutritionally complete enrichment treatsBio-ServF05478
Round Ice Bucket with Lid, 2.5 LCorning432129
Standard Plastic ClipboardStaples1227770
Steel wired 6' long movable shelving unitsUlineH9488Width/Height can be adjusted to need/number of rats per experiment
Sterile Saline 0.9%Covidien/Argyle1020For mixing with L-DOPA/bens

Tags

Parkinson Rat ModelSubcutaneous InjectionDopamine Conversion InhibitorL DOPA Benserazide MixDyskinesia Behavior RatingNeuronal OverstimulationBlood Brain Barrier CrossingSynaptic Dopamine ReleaseMotor Dysfunction Assessment